Featured Research

from universities, journals, and other organizations

Fertility treatment: Safer drug for women leads to same live birth rate, review suggests

Date:
May 10, 2011
Source:
Wiley-Blackwell
Summary:
With new information available, authors of a Cochrane Systematic Review have revised their conclusions about the relative effectiveness of two different treatments used to help women become pregnant. They now conclude that giving women gonadotrophin-releasing hormone antagonists leads to similar live-birth rates compared with GnRH agonists. Previously they had concluded that women who used antagonists tended to have lower birth-rates than those using agonists.

With new information available, authors of a Cochrane Systematic Review have revised their conclusions about the relative effectiveness of two different treatments used to help women become pregnant. They now conclude that giving women gonadotrophin-releasing hormone (GnRH) antagonists leads to similar live-birth rates compared with GnRH agonists. Previously they had concluded that women who used antagonists tended to have lower birth-rates than those using agonists.

This is important because the systematic review also showed that GnRH antagonists can halve the risk of over-stimulating the ovaries compared with GnRH agonists, as well as halving the number of women who have to pull out of a cycle of therapy.

To help women who are having difficulty becoming pregnant, doctors sometime treat them with hormone mimicking drugs that influence the way that eggs develop in their ovaries. One key danger of this is known as ovarian hyperstimulation syndrome (OHSS), which can be life-threatening for the woman. Previous advice was that women might like to consider using antagonists because they appeared to be safer, but should be counselled that their chance of becoming pregnant was lower.

In 2006, when the researchers reached their earlier conclusion, they were only able to draw data from 27 trials. Since then more research has been published, allowing them to consider the findings of 45 randomised controlled studies that involved a total of 7,511 women. "This increased amount of data lets us get a much better idea of how well the two approaches compare," says Dr Hesham Al-Inany, who was lead author of the research and works at Cairo University, Egypt. Dr Al-Inany led a multi-centre team, with researchers also based in the Netherlands and Canada.

"The reduction in ovarian hyperstimulation combined with a comparable live-birth rate mean justifies a move away from the standard GnRH agonist to using GnRH antagonists," says Dr Al-Inany.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Mohamed AFM Youssef, Fulco Van der Veen, Hesham G Al-Inany, Georg Griesinger, Monique H Mochtar, Ismail Aboulfoutouh, Sherif M. Khattab, Madelon van Wely. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database of Systematic Reviews, 2011 Issue 1 DOI: 10.1002/14651858.CD008046.pub3

Cite This Page:

Wiley-Blackwell. "Fertility treatment: Safer drug for women leads to same live birth rate, review suggests." ScienceDaily. ScienceDaily, 10 May 2011. <www.sciencedaily.com/releases/2011/05/110510211600.htm>.
Wiley-Blackwell. (2011, May 10). Fertility treatment: Safer drug for women leads to same live birth rate, review suggests. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/05/110510211600.htm
Wiley-Blackwell. "Fertility treatment: Safer drug for women leads to same live birth rate, review suggests." ScienceDaily. www.sciencedaily.com/releases/2011/05/110510211600.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins